Clinical Trials
21 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04789668 2026-03-18
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT07042243 2026-02-20
The Florida ASCENT Study
University of Florida
Phase NA Recruiting
NCT07286539 2025-12-16
PEPOH
University of Salamanca
Phase NA Not yet recruiting
NCT05323409 2025-09-19
Improving Comprehensive Care of Cancer Patients
Baylor College of Medicine
Phase NA Recruiting
NCT06582849 2025-08-26
EARN
Washington University School of Medicine
Phase NA Completed
NCT04827446 2025-07-09
Lighting Intervention for Cancer-related Fatigue
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT04035447 2025-06-29
Symptom Management for YA Cancer Survivors
Duke University
Phase NA Completed
NCT04896580 2025-02-26
IIT2020-20-SHIRAZIP-WALK: Nature Walks
Cedars-Sinai Medical Center
Phase NA Completed
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03219268 2023-12-21
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
Phase 1 Completed
NCT04190433 2023-05-24
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
Mayo Clinic
Phase 2 Withdrawn
NCT03919214 2023-04-19
Hypertension Management in Cancer Patients
Duke University
Phase NA Terminated
NCT02706392 2022-08-31
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT00526045 2020-12-17
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
Novartis
Phase 1/2 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT02431260 2019-06-14
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00962494 2013-02-07
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
Stanford University
Phase 2 Completed